Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration.
Identifieur interne : 002B94 ( PubMed/Curation ); précédent : 002B93; suivant : 002B95Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration.
Auteurs : Stefanie Klaffke [Allemagne] ; Andrea A. Kuhn ; Michail Plotkin ; Holger Amthauer ; Daniel Harnack ; Roland Felix ; Andreas KupschSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Aged, Benzamides (diagnostic use), Blood Glucose (metabolism), Brain (physiopathology), Brain (radionuclide imaging), Cerebral Cortex (physiopathology), Cerebral Cortex (radionuclide imaging), Cocaine (analogs & derivatives), Cocaine (diagnostic use), Corpus Striatum (physiopathology), Corpus Striatum (radionuclide imaging), Dominance, Cerebral (physiology), Female, Fluorodeoxyglucose F18 (diagnostic use), Humans, Male, Middle Aged, Parietal Lobe (physiopathology), Parietal Lobe (radionuclide imaging), Parkinsonian Disorders (physiopathology), Parkinsonian Disorders (radionuclide imaging), Positron-Emission Tomography, Pyrrolidines (diagnostic use), Receptors, Dopamine D2 (physiology), Tomography, Emission-Computed, Single-Photon, Tropanes (diagnostic use).
- MESH :
- chemical , analogs & derivatives : Cocaine.
- chemical , diagnostic use : Benzamides, Cocaine, Fluorodeoxyglucose F18, Pyrrolidines, Tropanes.
- chemical , metabolism : Blood Glucose.
- physiology : Dominance, Cerebral, Receptors, Dopamine D2.
- physiopathology : Brain, Cerebral Cortex, Corpus Striatum, Parietal Lobe, Parkinsonian Disorders.
- radionuclide imaging : Brain, Cerebral Cortex, Corpus Striatum, Parietal Lobe, Parkinsonian Disorders.
- Aged, Female, Humans, Male, Middle Aged, Positron-Emission Tomography, Tomography, Emission-Computed, Single-Photon.
Abstract
Alterations in presynaptic and postsynaptic dopaminergic system and cerebral glucose metabolism in corticobasal degeneration (CBD) were assessed to evaluate the potential usefulness of different imaging methods for CBD. (123)I-FP-CIT/(123)I-beta-CIT SPECT and (123)I-IBZM SPECT as well as (18)F-FDG PET were performed in eight CBD patients. Decreased presynaptic dopamine transporter binding was found in all CBD patients while D2 receptor binding was reduced in only one patient. (18)F-FDG PET displayed a contralateral hypometabolism in cortical and subcortical areas in seven out of eight patients. Our results demonstrate that glucose metabolism and DAT are reduced, while D2 receptors may be frequently preserved in CBD.
DOI: 10.1002/mds.21004
PubMed: 16773621
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002B94
Links to Exploration step
pubmed:16773621Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration.</title><author><name sortKey="Klaffke, Stefanie" sort="Klaffke, Stefanie" uniqKey="Klaffke S" first="Stefanie" last="Klaffke">Stefanie Klaffke</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University Medicine Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, University Medicine Berlin, Berlin</wicri:regionArea></affiliation></author><author><name sortKey="Kuhn, Andrea A" sort="Kuhn, Andrea A" uniqKey="Kuhn A" first="Andrea A" last="Kuhn">Andrea A. Kuhn</name></author><author><name sortKey="Plotkin, Michail" sort="Plotkin, Michail" uniqKey="Plotkin M" first="Michail" last="Plotkin">Michail Plotkin</name></author><author><name sortKey="Amthauer, Holger" sort="Amthauer, Holger" uniqKey="Amthauer H" first="Holger" last="Amthauer">Holger Amthauer</name></author><author><name sortKey="Harnack, Daniel" sort="Harnack, Daniel" uniqKey="Harnack D" first="Daniel" last="Harnack">Daniel Harnack</name></author><author><name sortKey="Felix, Roland" sort="Felix, Roland" uniqKey="Felix R" first="Roland" last="Felix">Roland Felix</name></author><author><name sortKey="Kupsch, Andreas" sort="Kupsch, Andreas" uniqKey="Kupsch A" first="Andreas" last="Kupsch">Andreas Kupsch</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.21004</idno><idno type="RBID">pubmed:16773621</idno><idno type="pmid">16773621</idno><idno type="wicri:Area/PubMed/Corpus">002B94</idno><idno type="wicri:Area/PubMed/Curation">002B94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration.</title><author><name sortKey="Klaffke, Stefanie" sort="Klaffke, Stefanie" uniqKey="Klaffke S" first="Stefanie" last="Klaffke">Stefanie Klaffke</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University Medicine Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, University Medicine Berlin, Berlin</wicri:regionArea></affiliation></author><author><name sortKey="Kuhn, Andrea A" sort="Kuhn, Andrea A" uniqKey="Kuhn A" first="Andrea A" last="Kuhn">Andrea A. Kuhn</name></author><author><name sortKey="Plotkin, Michail" sort="Plotkin, Michail" uniqKey="Plotkin M" first="Michail" last="Plotkin">Michail Plotkin</name></author><author><name sortKey="Amthauer, Holger" sort="Amthauer, Holger" uniqKey="Amthauer H" first="Holger" last="Amthauer">Holger Amthauer</name></author><author><name sortKey="Harnack, Daniel" sort="Harnack, Daniel" uniqKey="Harnack D" first="Daniel" last="Harnack">Daniel Harnack</name></author><author><name sortKey="Felix, Roland" sort="Felix, Roland" uniqKey="Felix R" first="Roland" last="Felix">Roland Felix</name></author><author><name sortKey="Kupsch, Andreas" sort="Kupsch, Andreas" uniqKey="Kupsch A" first="Andreas" last="Kupsch">Andreas Kupsch</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Benzamides (diagnostic use)</term><term>Blood Glucose (metabolism)</term><term>Brain (physiopathology)</term><term>Brain (radionuclide imaging)</term><term>Cerebral Cortex (physiopathology)</term><term>Cerebral Cortex (radionuclide imaging)</term><term>Cocaine (analogs & derivatives)</term><term>Cocaine (diagnostic use)</term><term>Corpus Striatum (physiopathology)</term><term>Corpus Striatum (radionuclide imaging)</term><term>Dominance, Cerebral (physiology)</term><term>Female</term><term>Fluorodeoxyglucose F18 (diagnostic use)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parietal Lobe (physiopathology)</term><term>Parietal Lobe (radionuclide imaging)</term><term>Parkinsonian Disorders (physiopathology)</term><term>Parkinsonian Disorders (radionuclide imaging)</term><term>Positron-Emission Tomography</term><term>Pyrrolidines (diagnostic use)</term><term>Receptors, Dopamine D2 (physiology)</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Tropanes (diagnostic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Cocaine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Benzamides</term><term>Cocaine</term><term>Fluorodeoxyglucose F18</term><term>Pyrrolidines</term><term>Tropanes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Dominance, Cerebral</term><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term><term>Cerebral Cortex</term><term>Corpus Striatum</term><term>Parietal Lobe</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Brain</term><term>Cerebral Cortex</term><term>Corpus Striatum</term><term>Parietal Lobe</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Positron-Emission Tomography</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Alterations in presynaptic and postsynaptic dopaminergic system and cerebral glucose metabolism in corticobasal degeneration (CBD) were assessed to evaluate the potential usefulness of different imaging methods for CBD. (123)I-FP-CIT/(123)I-beta-CIT SPECT and (123)I-IBZM SPECT as well as (18)F-FDG PET were performed in eight CBD patients. Decreased presynaptic dopamine transporter binding was found in all CBD patients while D2 receptor binding was reduced in only one patient. (18)F-FDG PET displayed a contralateral hypometabolism in cortical and subcortical areas in seven out of eight patients. Our results demonstrate that glucose metabolism and DAT are reduced, while D2 receptors may be frequently preserved in CBD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16773621</PMID><DateCreated><Year>2006</Year><Month>10</Month><Day>26</Day></DateCreated><DateCompleted><Year>2007</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2006</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration.</ArticleTitle><Pagination><MedlinePgn>1724-7</MedlinePgn></Pagination><Abstract><AbstractText>Alterations in presynaptic and postsynaptic dopaminergic system and cerebral glucose metabolism in corticobasal degeneration (CBD) were assessed to evaluate the potential usefulness of different imaging methods for CBD. (123)I-FP-CIT/(123)I-beta-CIT SPECT and (123)I-IBZM SPECT as well as (18)F-FDG PET were performed in eight CBD patients. Decreased presynaptic dopamine transporter binding was found in all CBD patients while D2 receptor binding was reduced in only one patient. (18)F-FDG PET displayed a contralateral hypometabolism in cortical and subcortical areas in seven out of eight patients. Our results demonstrate that glucose metabolism and DAT are reduced, while D2 receptors may be frequently preserved in CBD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klaffke</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medicine Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Andrea A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Plotkin</LastName><ForeName>Michail</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Amthauer</LastName><ForeName>Holger</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Harnack</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Felix</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kupsch</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014326">Tropanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>133647-95-7</RegistryNumber><NameOfSubstance UI="C069723">RTI 55</NameOfSubstance></Chemical><Chemical><RegistryNumber>155797-99-2</RegistryNumber><NameOfSubstance UI="C087552">2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane</NameOfSubstance></Chemical><Chemical><RegistryNumber>84226-06-2</RegistryNumber><NameOfSubstance UI="C055743">3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>I5Y540LHVR</RegistryNumber><NameOfSubstance UI="D003042">Cocaine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002540">Cerebral Cortex</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004292">Dominance, Cerebral</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019788">Fluorodeoxyglucose F18</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010296">Parietal Lobe</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D049268">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011759">Pyrrolidines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017448">Receptors, Dopamine D2</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014326">Tropanes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21004</ArticleId><ArticleId IdType="pubmed">16773621</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002B94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16773621
|texte= Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16773621" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |